Otsuka Bolsters Oncology Stable With IV Busulfex Acquisition
This article was originally published in PharmAsia News
Executive Summary
Otsuka looks to be strengthening its oncology business with the acquisition of PDL BioPharma's IV Busulfex (busulfan), the company's second cancer product acquisition of the year